Immunoproteasome inhibitor analogs
US10584105B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 10, 2017 |
| Grant date | Mar 10, 2020 |
| Priority date | — |
| Expiry date | Mar 10, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K5/06052
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides for compounds having immunoproteasome inhibitory activity, and pharmaceutical compositions made thereof. The disclosure further provides for the use of the compounds and compositions in treating various diseases and disorders in a subject that are associated with immunoproteasome activity, including inflammatory disorders, autoimmune disorders, hematological disorders, and neurodegenerative disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.